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Abstract.  Thrombospondin is one of a class of adhe- 
sive glycoproteins that mediate cell-to-cell and cell- 
to-matrix interactions.  We have used two monoclonal 
antibodies to isolate cDNA clones of thrombospondin 
from a human endothelial cell cDNA library and have 
determined the complete nucleotide sequence of the 
coding region.  Three regions of known amino acid se- 
quence of human platelet thrombospondin confirm that 
the clones are authentic.  Three types of repeating 
amino acid sequence are present in thrombospondin. 
The first is 57 amino acids long and shows homology 
with circumsporozoite protein from Plasmodium fal- 
ciparum. The second is 50-60 amino acids long and 
shows homology with epidermal growth factor precur- 
sor.  The third occurs as a continuous eightfold repeat 
of a 38-residue sequence;  structural homology with 
parvalbumin  and calmodulin indicates that these 
repots constitute the multiple calcium-binding  sites of 
thrombospondin.  The amino acid sequence arg-gly- 
asp-ala is included in the last type 3 repeat.  This se- 
quence is probably the site for the association of 
thrombospondin with cells. In addition,  localized ho- 
mologies with procollagen,  fibronectin, and von 
Willebrand factor are present in one region of the 
thrombospondin molecule. 
T  HROMBOSPONDIN is a  420,000-D  glycoprotein  that 
was first identified in human blood platelets and then 
shown to be synthesized and secreted by various cells 
in culture (for a review see Lawter,  1986). Thrombospondin 
secreted from activated platelets becomes associated with the 
platelet  membrane  and  incorporated  into  the  developing 
fibrin clot (Bale et al.,  1985; Murphy-UUrich  and Mosher, 
1985; Wolff et al., 1986). Thrombospondin secreted by cells 
in culture is incorporated into the extracellular  matrix (Raugi 
et al., 1982; Jaffe et al., 1983; McKeown-Longo et al., 1984; 
Majack et al.,  1985). In vitro binding  studies  indicate  that 
thrombospondin can bind to fibrinogen,  fibronectin,  lami- 
nin, and type V collagen (Leung and Nachman, 1982; Lahav 
et  al.,  1982, 1984; Mumby et  al.,  1984; Lawler et  al., 
1986b). These data suggest that thrombospondin is a mem- 
ber of a class of adhesive proteins  that mediate  cell-to-cell 
and cell-to-matrix  interactions  (Hynes, 1985). 
Thrombospondin is composed of three polypeptide chains 
that  are cross-linked by disulfide  bonds and appear to be 
identical  in terms of molecular weight,  position of cleavage 
sites for thrombin, plasmin,  thermolysin, and trypsin, and 
l~;It2-terminal  amino  acid  sequence  (Lawler  and  Slayter, 
1981; Dixit et al.,  1984; Raugi  et al.,  1984; Coligan  and 
Slayter,  1984; Lawler et al., 1985; Galvin et al., 1985). Re- 
cent immunological,  biochemical, and electron microscopic 
data permit the formulation of models for the structure of hu- 
man platelet thrombospondin (Lawler et al., 1985; Galvin et 
al., 1985). Electron microscopy of replicas produced by low 
angle  rotary shadowing  indicates  that  the thrombospondin 
molecule can be divided into four distinct structural regions; 
globular region  N,  a  region  where the chains  are cross- 
linked,  a  thin,  connecting  region,  and globular region C. 
Globular region N is composed of three 25,000-D segments 
of polypeptide  which  are  the  NH2-terminal  segments  of 
each chain. This region has been shown to mediate the bind- 
ing of thrombospondin to heparin  (Lawler and Slayter, 1981; 
Dixit et al.,  1984). In addition,  polyclonal antibodies pre- 
pared against globular region N inhibit platelet aggregation 
(Gartner et al.,  1984). 
The thin,  connecting  region appears,  by electron micros- 
copy, to be flexible and its length increases by ~30% when 
calcium is removed from the molecule (Lawler et al.,  1985; 
Dixit et al., 1986). Chymotryptic digestion of thrombospon- 
din in the absence of calcium produces a 210,000-D trimeric 
structure  composed of the  thin,  connecting  regions  from 
each  of the  three  chains  and  the  site  where  the  chains 
are cross-linked  (Mumby et al.,  1984; Galvin et al.,  1985; 
Lawler et al., 1986b). This fragment has been shown to bind 
type V collagen,  fibronectin,  fibrinogen,  plasminogen,  and 
laminin in solid-phase  binding assays (Mumby et al.,  1984; 
Lawler et al.,  1986b). 
The final distinct  structural  region of thrombospondin is 
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appears at the ends of each of the thin,  connecting regions 
(Lawler et al., 1985; Galvin et al.,  1985). Dixit et al. (1985) 
have reported that a monoclonal antibody against this region 
of thrombospondin inhibits platelet aggregation. These data, 
in conjunction with the data of Gartner et ai. (1984),  suggest 
that multiple sites in the thrombospondin molecule are in- 
volved in platelet  aggregation.  In the presence of EDTA, 
globular region C decreases in size, concomitant with the in- 
crease in length of the thin,  connecting region,  suggesting 
that there is a redistribution of mass from globular region C 
to the thin,  connecting  region  (Lawler et al.,  1985).  This 
conformational  change can also be detected by changes in 
sedimentation  coefficient,  intrinsic  viscosity,  circular  di- 
chroism, and the peptide pattern produced by limited tryptic 
digestion (Lawler et al.,  1982;  Lawler and Simons,  1983). 
These methods indicate that the transition occurs at 50-120 
~tM calcium concentration by a cooperative mechanism that 
involves at least 12 calcium-binding  sites. 
While these biochemical and electron microscopic studies 
have helped to define the overall shape of the thrombospon- 
din molecule, very little is known of the primary or second- 
ary structure. In this paper we report the cloning of throm- 
bospondin from a eDNA library constructed from human 
endothelial cell mRNA in Lgtll.  The complete amino acid 
sequence has been determined from the nucleotide sequence 
of the coding region. These studies permit (a) the identifica- 
tion of internal repeating sequences within the thrombospon- 
din molecule, (b) the comparison of thrombospondin struc- 
tures with other proteins,  and (c) interpretation  of some of 
the functional properties of thrombospondin on a structural 
level. 
Materials and Methods 
Materials 
A Lgtll bacteriophage library of  eDNA derived from cultured human umbil- 
ical vein endothelial cells and E. coli strains Y1088, Y1089, and Y1090 were 
kindly provided by Dr. Robert Handin. A pool of random hexanucleotides 
was used as the primer for eDNA synthesis (Ginsburg et al.,  1985).  Two 
monoclonal antibodies, designated MA-I and MA-II, which were raised 
against human platelet thrombospondin, were used in this study (Lawler et 
al., 1985). The epitope for MA-II is located in the NH2-terminal 25,000-D 
heparin-binding fragment, while the epitope for MA-I is located in a region 
of polypeptide that is adjacent to a 25,000-D COOH-terminal tryptic frag- 
ment (Lawler et al., 1985). All enzymes were purchased from New England 
Biolabs (Beverly,  MA) except where otherwise noted. 
Antibody Screening of  Recombinant Phage 
A total of 150,000 phage were adsorbed to E. coli strain Y1090, plated at 
a  density of 20,000  plaque-forming units/15-cm L2-ampicillin plate, and 
grown at 42°C for 4 h (Young and Davis, 1985).  Nitrocellulose filters (0.2 
~tm;  Schleicher &  Schuell,  Inc.,  Keene,  NH)  were  soaked  in  10  mM 
isopropyl-13-v-thiogalactopyranoside and dried.  Filters were overlaid on 
plaques and [~-galactosidase fusion protein synthesis was induced for 2 h at 
37°C (Young and Davis, 1985). The filters were keyed to the plates, washed 
briefly in 0.05  M  Tris HC1 (pH 8.0),  0.15 M  NaC1 and 0.2%  Tween 20 
(TBST), and incubated for 1-2 h in TBST containing 5 % bovine serum albu- 
min (BSA). A second filter was overlaid on the plates and incubated at 37°C 
for 1 h.  After incubation in TBST containing 5%  BSA, the filters were 
washed three times with TBST during a 30-min period and were then in- 
cubated with TBST containing either MA-I or MA-H (1:250 vol/vol) over- 
night at 22°C with gentle mixing. The antibody solutions were saved and 
reused in subsequent screening rounds. The filters were washed with TBST 
and the antibodies were localized with biotinylated second antibody fol- 
lowed  by  avidin-biotin-peroxidase complex  (Vector  Laboratories,  Inc., 
Budingame, CA). Plaques that produced positive signals in the first high 
density screen were taken through four to eight successive rounds of anti- 
body screening at progressively lower plaque densities. The resulting, re- 
peatedly positive, and well isolated phage plaques were picked, amplified 
to yield high titre plate stocks, and used for the large scale preparation of 
phage (Maniatis et al., 1978). Recombinant phage DNA was isolated from 
induced lysogens by a previously described procedure (Pirrotta et al., 1971). 
Lysogens were prepared from each clone by infection of E. coli strain Y1089 
at a multiplicity of infection of 5 (I-Iynes et al., 1986). Fusion proteins were 
identified  by SDS PAGE (Laemmli, 1970). The proteins were electrophoreti- 
tally transferred to nitrocellulose paper, and the replicas were probed with 
MA-I and MA-1I as described previously (Lawler et al.,  1985). 
Subcloning and Sequence Determination 
All sequencing was done by the chain termination method of Sanger et al. 
(1977) with dideoxy sequencing reagents (th'omega Biotec, Madison, WI) 
and standard procedures suggested  by the supplier. Reactions were generally 
performed at 37* or 40°C; however, some regions were also sequenced at 
550C. The subcloning and nucleotide sequencing strategy is summarized in 
the following steps. 
Step 1.  Purified recombinant phage DNA was digested with KpnI and 
Sad and the nucleotide sequence of the 5' end of the insert was determined 
using a Lgtll primer (New England Biolabs). 
Step 2. Phage DNA was subjected to EcoRI or PstI endonuclease diges- 
tion and the inserts or fragments were separated by agarose gel eleetrophore- 
sis (Maniatis et al., 1982) (Fig.  1, b and c). DNA was eluted by the glass 
bead method of Vogelstein and Gillespie (1979) and subcloned into the 
appropriate sites of the Riboprobe Gemini transcription vector pGEM-2 
(Promega Biotec). The nucleotide sequences of the 5' and 3' ends of each 
of  the inserts were determined using oligonucleotide  primers to the SP6 and 
T7 promoters of the vector (Promega Biotec). 
Step 3. Ordered sets of deletion clones of the major PstI fragments were 
generated by exonuclease HI deletion essentially as described by Henikoff 
(1984) (Fig. 1 c). Briefly,  10 p.g of purified plasmid DNA was sequentially 
digested with SacI and Baml-II. The sample was extracted with an equal vol- 
ume of phenol/chloroform (1:1 vol/vol) and then precipitated with ethanol. 
The pellet was dissolved in 60 ~tl of 66 mM Tris-HCi (pH 8.0) and 0.66 mM 
MgCi2, then 500 U  of exonuclease HI was added.  The sample was in- 
cubated at 35°C. At 20-s intervals 2.5-~tl samples were removed and mixed 
with 7.5 I.tl of 0.3 M KOAC (pH 4.6), 0.5 M NaCI, 4.5% glycerol, 16.7 mM, 
ZnSO4,  and 220 U/ml S1 nuclease (Boehringer-Mannheim Biochemicals, 
Indianapolis, IN) and incubated at 0°C. After all of the time points were 
collected, the samples were incubated at 22°C for 30 min,  1 td of 0.3 M 
Tris and 0.05 M EDTA was added to each, and the samples were heated to 
70°C for 10 min. A 2-~tl aliquot of each sample was removed for agarose 
gel electrophoresis. 1 gl of 20 mM Tris-HCl (pH 8.0),  1(30 mM MgCI2, 
and 100 U/ml large fragment DNA polymerase I were added and the sam- 
pies were incubated at 37°C. After 2 min, 1 I~1 of a mixture containing 0.125 
mM dGTP,  0.125 mM dATP, 0.125 mM dTTP, and 0.125 mM dCTP was 
added and the samples were incubated at 37°C for 5 min. The samples were 
heated to 70°C for 10 min, a 1/10 vol of 0.66 M Tris-HC1  (pH 7.6), 50 mM 
MgCI2, 50 mM dithiothreitol, and 10 mM ATP was added, and they were 
incubated with 100-400 U of T4 DNA ligase at 220C  for 18 h. 
Step 4. Additional PvulI, XnmI, BamH1, Sinai, and AccI fragments were 
subcloned and sequenced to resolve ambiguities, to confirm the termination 
codon, and to cross the EcoR1  and PstI sites (Fig.  1 d). 
Northern Blot Hybridization 
Total cellular RNA was isolated as described previously (Schwarzbauer et 
al., 1983) from cultured human umbilical vein endothelial cells, which were 
kindly  provided by  Dr.  Robert Weinstein.  RNA  was  separated  in  1% 
agarose-formaldehyde  gels and transferred to nitrocellulose paper (0.45 Ixm; 
Schleicher & Schuell, Inc.). A hybridization probe was prepared from the 
M5 insert by EcoRI digestion and preparative agarose gel electrophoresis 
followed by nick-translation to a  specific activity of l0  s cpm/Ixg.  Blots 
were prehybridized at 42°C for 3 h in a solution of 5 x  Denhardt's, 5 x  stan- 
dard saline citrate (SSC), 50%  formamide,  100 mM Na phosphate, and 
0.1% SDS containing 100 t~g/ml E. coli DNA and 5% dextran sulfate. Hy- 
bridization was done in the same buffer at 42°C for 12-16 h with 10% dex- 
tran sulfate and 0.5-1.0  x  107 cpm/lane of nick-translated probe. Filters 
were washed at 68"C in several changes of2x  SSC, 0.1% SDS (moderate 
stringency) followed by 0.1×  SSC, 0.1% SDS (high stringency). Molecular 
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Figure 1. Alignment of human thrombospondin clones. (a) Restriction map showing endonuclease sites used to align the original cDNA 
clones and to subclone fragments for sequencing. (b) The original eDNA clones selected by MA-I and MA-II from the human endothelial 
cell eDNA library. (c) eDNA subclones produced for nucleotide sequencing by exonuclease HI deletion of the major PstI fragments. (d) 
Additional subclones produced by BamHI, SmaI, PvuII, XmnI, and AccI digestion to complete the determination of the nucleotide se- 
quence. Both ends of all clones were sequenced to generate a complete sequence. 
weights were determined by comparison with rRNA and RNA size markers 
(Bethesda Research Laboratories,  Gaithersburg,  MD). 
Results 
Isolation of  cDNA Clones 
Seven clones, designated M1-M7, were selected and plaque- 
purified using immunoscreening with the monoclonal anti- 
body MA-I (Fig.  1 b).  Three clones, designated M9-Mll, 
were selected and plaque-purified with MA-II (Fig. 1 b). In- 
spection of the filters revealed that the plaques produced by 
the M10 clone stained with MA-I in addition to MA-II, sug- 
gesting that this 3.3-kbp insert encoded a fusion protein that 
contained the epitopes for both antibodies.  The eDNA in- 
serts  were  oriented and  aligned based  on  restriction en- 
donuclease sites and the known positions of the epitopes for 
the monoclonal antibodies. The antibody results indicate that 
M9 and Mll must be near the 5' end of the map,  whereas 
M1-M7 must be near the 3' end and MI0 should overlap both 
sets of clones. In addition, the nucleotide sequence of the 5' 
end of each insert was determined by the chain termination 
method of Sanger etal. (1977) with a Lgtll primer. These se- 
quence data facilitated the subsequent subcloning and se- 
quence determination by identifying the 5' end of each insert 
and the correct reading frame. 
The restriction map indicates that the 10 clones correspond 
to ~v5 kbp of nucleotide sequence. Northern blot analysis of 
human endothelial cell RNA using clone M5 gave a major 
band of 6.1 kbp, indicating that the mRNA is ,'~1.1 kbp larger 
than the cloned region (data not shown). Minor bands were 
also observed at 4.6, 4.2, and 3.8 kbp on the Northern blot, 
however we have not investigated this heterogeneity in detail 
(data not shown). 
Determination of the Nucleotide Sequence 
Nested sets of  overlapping clones of  the major PstI fragments 
were generated by exonuclease I/I digestion (Fig. 1 c). These 
clones and the original inserts were sequenced by the method 
of Sanger et al. (1977). The 5' end of each insert, as well as 
three regions of known amino acid sequence (see below), 
provided thirteen checks of the reading frame. The final am- 
biguities  and  the position of the termination  codon were 
resolved  by  subcloning  fragments  produced  by  BamHI, 
Sinai,  PvuII,  XmnI,  and  AccI digestion  (Fig.  1 d).  The 
nucleotide sequence was determined in multiple overlapping 
clones, and ,~,70% of the coding region (see below) was de- 
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 3601  TGATTGAAAGACTGATCATAAACCAATGCTGGTATTGCACCTTCTGGAACTATGGGCTTG 
3661  AGAAAACCCCCAGGATCACTTCTCCTTGGCTTCCTTCTTTTCTGTGCTTGCATCAGTGTG 
3721  GACTCCTAGAACGTGCGACCTGCCTCAAGAAAATGCAGTTTTCAAAAACAGACTCAGCAT 
3781  TCAGCCTCCAATGAATAAGACATCTTCCAAGCATATAAACAATTGCTTTGGTTTCCTTTT 
3841  GAAAAAGCATCTACTTGCTTCAGTTGGGAAGGTGCCCATTCCACTCTGCCTTTGTCACAG 
3901  AGCAGGGTGCTATTGTGAGGCCATCTCTGAGCAGTGGACTCAAAAGCATTTTCAGGCATG 
3961  TCAGAGAAGGGAGGACTCACTAGAATTAGCAAACAAAACCACCCTGACATCCTCCTTCAG 
4021  GAACACGGGGAGCAGAGGCCAAAGCACTAAGGGGAGGGCGCATACCCGAGACGATTGTAT 
4081  GAAGAAAATATGGAGGAACTGTTACATGTTCGGTACTAAGTCATTTTCAGGGGATTGAAA 
4141  GACTATTGCTGGATTTCATGATGCTGACTGGCGTTAGCTGATTAACCCATGTAAATAGGC 
4201  ACTTAAATAGAAGCAGGAAAGGGAGACAAAGACTGGCTTCTGGACTTCCTCCCTGATCCC 
4261  CACCCTTACTCATCACCTGCAGTGGCCAGAATTAGGGAATCAGAATCGAAACCAGTGTAA 
4321  GGCAGTGCTGGCTGCCATTGCCTGGTCACATTGAAATTGGTGGCTTCATTCTAGATGTAG 
4381  CT TGTGCAGATGTAGCAGGAAAATAGGAAAACCTACCATCTCAGTGAGCACCAG 
Figure 2. Nucleotide sequence of cDNA clones and corresponding amino acid sequence. The initiation and termination codons are boxed. 
The NH2 terminal (asterisks) and cysteine residues (solid arrowheads) are indicated and the regions of known amino acid sequence are 
underlined. The potential sites for addition of N-linked carbohydrate are marked by open triangles. The amino acid sequence is given in 
the single letter code. 
termined on both strands. The results established a continu- 
ous sequence of 4,434 bases from the 5' end of M10 to the 
PvulI site just beyond the 3' end of M2 (Fig. 2). The region 
between the 3' end of M2 and that of M6 was not completely 
sequenced because this region was determined to be noncod- 
ing (see below). 
The cDNA sequence has the following features. A con- 
sensus sequence (ACCATGG) for initiation codons begins at 
position 73 (Fig. 2) (Kozak, 1986).  The initiation codon is 
followed by an open reading frame of 3,508 bases and a TAA 
termination codon at position 3,586.  The coding region is 
followed by 848 bases of 3' untranslated sequence. An addi- 
tional 140 bases have been determined by sequencing the 3' 
end of M6  (Fig.  1).  Both segments of 3' untranslated se- 
quence have multiple termination codons in all three frames, 
but do not include a polyadenylation signal sequence. These 
data are consistent with the Northern blotting data which in- 
dicate that the thrombospondin message is 6.1 kb, presum- 
ably including more 3' untranslated sequences that are not 
included in our clones. 
Amino Acid Sequence 
The cDNA sequence predicts that the mature thrombospon- 
din chains (i.e., minus the signal sequence, see below) are 
composed of 1,152 amino acids and have a molecular weight 
of 127,524 without carbohydrate (Fig.  2).  The amino acid 
composition  of  the  predicted  polypeptide  (K,55;  H,26; 
R,60; D,131; N,81; E,51; Q,50; T,61; S,74; G,101; A,50; C,69; 
M,12; V,70; P,70; 1,45; L,60; F,34; Y,31; W,21) agrees well 
with previously published compositions for thrombospondin 
(Lawler et al.,  1978). 
Three regions of known amino acid sequence of human 
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Figure 3. Alignment of type 1 homologies. The four type I homologies (three complete and one partial) are aligned with the position of 
the first and last amino acids in the complete thrombospondin sequence indicated to the right of each line. Regions where two or more 
of the four aligned residues are identical are enclosed in boxes. Dashes indicate gaps introduced to maximize alignment. The amino acid 
sequence of a homologous region from the circumsporozoite (CS) protein of  Plasraodiumfalciparum  is given at the bottom with homologous 
residues enclosed in boxes (Dame et al., 1984). Note that the CS protein sequence lacks the central pair of cysteine residues present in 
the thrombospondin repeats. 
platelet thrombospondin can be identified. The amino acid 
sequence between N(1) and G(25) is identical with the re- 
ported sequence for the NH2-terminal of the thrombospon- 
din chains, with one exception (Coligan and Slayter, 1984; 
Dixit et al., 1984; Raugi et al., 1984). Arginine (23) has pre- 
viously been reported to be tryptophan (Coligan and Slayter, 
1984).  The amino acid sequence between 1(241) and I(251) 
is identical with the reported sequence for the NH2 terminal 
of a  70,000-D  chymotryptic fragment of thrombospondin 
(Galvin et al.,  1985).  In addition, the amino acid sequence 
between D(1031) and Y(1046)  is identical with the reported 
sequence for the NH2 terminal of an 18,000-D chymotryptic 
fragment of thrombospondin (Galvin et al.,  1985).  These 
data prove that the M1-M7 and M9-Mll clones are authentic 
clones of human thrombospondin. 
The predicted amino  acid  sequence of thrombospondin 
has the following features. The NH2 terminal N(1) is pre- 
ceeded by an  18 amino acid signal sequence of uncharged 
residues (-18 to -1). The majority of the cysteine residues 
are located in the center one-third of the molecule. Three 
types of repeating sequence, designated homology types 1-3, 
occur within the amino acid sequence (see below). There are 
six potential sites for N-linked glycosylation, although two 
of them include proline and are less likely to be used (Fig. 
2) (Hubbard and Ivatt,  1981). 
The amino acid sequences of the type 1 homologies are 
shown in Fig.  3.  Three complete type 1 homologies of 57 
amino acids occur between D(361) and 1(530). Alignment of 
these three segments reveals that 30%  of the residues are 
identical in all three and that the positions of all six cysteine 
residues are conserved (Fig. 3). In addition, the region be- 
tween C(321)  and 1(337) was  found to be homologous with 
the last  17 amino acids of the type  1 repeating sequences 
(Fig. 3). 
Three adjacent type 2 homologies follow immediately af- 
ter the type 1 homologies (Fig. 4). Six cysteine residues oc- 
cur in each of the three repeats along with other conserved 
residues (Fig. 4).  The type 2  repeats are not as well con- 
served as the type 1 homologies. The second type 2 repeat 
shows the least homology with the other two (Fig. 4). A se- 
quence of 13 amino acids (positions 42-54) is present in this 
repeat only. Ignoring this insertion and with other gaps as 
in Fig. 4, the repeats show 30-35 % pairwise identity (20% 
threefold identity) over 46 residues. 
The amino acid sequences of the type 3 homology region 
are shown in Fig. 5. This region includes eight repeating se- 
quences that show a well conserved pattern 38 amino acids 
long.  The eight type 3  homologies form a  continuous se- 
quence of 260 amino acids.  A  consensus sequence for the 
type 3 repeats shows that aspartate (D) occupies 11 of the 38 
positions (Fig. 5). In addition, the spacing of the D residues 
and one of  the glycine (G) residues in the first half of the con- 
sensus sequence (positions 6-17) is recapitulated in the sec- 
ond half of the consensus sequence (positions 21-32). These 
sequences are homologous with the calcium-binding sites of 
parvalbumin and calmodulin (see Discussion). 
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Figure 4. Alignment of type 2 homologies. The three type 2 homologies are aligned with the positions of the first and last amino acids 
in the complete amino acid sequence of thrombospondin indicated at the right. The sequence is continuous from D(531) to D(674). The 
amino acid sequence of the homologous region of mouse epidermal growth factor precursor (EGFP) is given at the bottom with the charac- 
teristic cysteine residues enclosed in boxes (Gray et al.,  1983; Scott et al.,  1983). 
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Figure 5.  Alignment of type 3 homologies. The eight type 3 homologies are aligned with the positions of the first and last amino acids 
in the complete amino acid sequence of thrombospondin indicated at the right. The sequence given is continuous from G(672) to V(932). 
This sequence follows directly after the type 2 homologies shown in Fig. 4. A consensus sequence of the most strongly conserved amino 
acids is indicated at the bottom. Note that the pattern of  aspartate (D) residues, which probably constitutes a calcium-binding site, is repeated 
twice in the type 3A repeats. The second half of each of the type 3A repeats, which is absent in the two type 3B repeats is bracketed. 
The first repeat (3/1) appears to be a hybrid of type 3 and type 1 homologies (see text). The RGDA sequence, a potential cell-binding 
site, is enclosed in the dashed box. Dashes indicate where the sequences have been gapped to maximize alignment. Regions where four 
or more of the aligned residues are identical are enclosed in boxes. 
The type 3  repeating sequences can be subdivided into 
three subtypes. The first subtype, designated 3A, includes 
five of the eight repeating sequences (Fig. 5). The type 3A 
repeats conform to the consensus sequence and include both 
putative calcium-binding sites. The second subtype, desig- 
nated 3B, occurs twice (Fig. 5). Positions 17-31, constituting 
one of  the two calcium binding sites, are absent from the type 
3B homologies. The third subtype, designated 3/1, shows the 
least homology with types 3A and 3B (Fig. 5). Positions 6, 
8, and 10 are occupied by D and position 11 is occupied by 
G as in the consensus sequence. However, the latter half (po- 
sitions 21-38) of this repeat is dissimilar to the consensus se- 
quence (Fig. 5). The latter half of the 3/1 repeat is instead 
homologous with the last  17 residues of the type 1 repeats 
(Fig. 3). This repeat, therefore, appears to be a hybrid of  type 
3 and type 1 homologies. 
Discussion 
The data presented here indicate that each of the three chains 
of thrombospondin has a molecular weight of 127,524 with- 
out carbohydrate. A mass of 10,000 D has been reported for 
the  carbohydrate groups,  bringing  the total mass  of each 
chain to ,~138,000 D (Vischer et al., 1985). This value agrees 
well with molecular weights of 133,000 determined by sedi- 
mentation  equilibrium  and  145,000  determined  by  SDS 
PAGE on phosphate-buffered gels (Margossian et al.,  1981; 
Eawler et al.,  1982).  These data indicate that the value of 
185,000 obtained by SDS PAGE by the method of Laemmli 
(1970) is an overestimate (Lawler et al., 1982; and see Fig. 6). 
The amino acid sequence obtained in this study for endo- 
thelial cell thrombospondin is consistent with earlier struc- 
tural studies of platelet thrombospondin. The amino acid se- 
quence predicts that there is a peptide of 26,173 D, with one 
glycosylation site, between the NH2 terminus of the intact 
molecule and the NH2 terminus of the 70,000-D chymotryp- 
tic fragment (Fig. 6) (Galvin et al., 1985). The glycosylation 
site is eleven residues from the COOH-terminus of this frag- 
ment.  Chymotryptic digestion at low  enzyme-to-substrate 
ratios results in the production of a 30,000-D fragment which 
binds the Lens culinaris lectin (Lawler et al.,  1986a).  At 
higher enzyme-to-substrate ratios the 30,000-D fragment is 
converted to a 25,000-D fragment which no longer binds the 
lectin.  Since the  NH2-terminal sequence of the  25,000-D 
fragment is identical to that of the intact molecule, it can be 
concluded that the carbohydrate is near the COOH terminal 
of the 30,000-D fragment (Galvin et al., 1985; Lawler et al., 
1986a)  exactly as predicted by the sequence. 
The 25,000-D fragment also contains the epitope for MA- 
Il (Lawler et al., 1985), consistent with the fact that this re- 
gion is  encoded by the  clones M9  and  Mll,  which  were 
selected by MA-II (Figs.  1 and 6). The 25,000-D fragment 
also contains the binding site for heparin (Lawler and Slay- 
ter,  1981; Dixit et al.,  1984).  Two possible heparin-bind- 
ing sites can be identified in this region. Clusters of posi- 
tively charged amino acids exist between R(23) and K(32) 
and between R(77)  and R(83).  The latter segment is pre- 
dicted to be in an a-helical conformation by the algorithm 
of Chou and Fasman (1978), as is the heparin-binding region 
of platelet factor 4  and 13-thromboglobulin  (Lawler,  1981). 
The 70,000-D chymotryptic fragment (see Fig. 6) contains 
the sites where the chains are cross-linked by disulfide bonds 
and binds Lens culinaris lectin (Lawler et al.,  1985; Galvin 
et al.,  1985; Lawler et al.,  1986). Consistent with these ob- 
servations, the sequence that follows the NH2 terminal of 
the 70,000-D fragment is rich in cysteine and includes three 
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Figure 6. Correlation of  the primary sequence data with the proper- 
ties of the major proteolytic fragments of thrombospondin. The po- 
sition of the types 1 (open diamond), 2 (open circle), and 3 (open 
rectangle) repeats are indicated at the top. The open boxes at the 
NH2 terminal and COOH terminal are regions where strong repeat- 
ing sequences could not be identified. The locations of known amino 
acid sequence are indicated (asterisk). NGS, NAT, NPT, and NST 
mark sequences of potential asparagine linked carbohydrate accep- 
tor sites (NxT and NxS). RGDA (arg-gly-asp-ala) marks a potential 
cell-binding site. The masses of the fragments produced by trypsin 
(T) and chymotrypsin (C) are indicated underneath each fragment. 
The sites for thrombin (thr) cleavage are indicated by arrows. Those 
fragments which contain carbohydrate moieties (open hexagon) 
which bind Lens culinaris lectin are indicated. The position and 
number of Lens culinaris lectin binding sites within the 85,000-D 
tryptic fragment (T-85,000) has not been determined. The molecu- 
lar weights given in this figure are based on the migration in the 
Laemmli gel system which overestimates the size of thrombospon- 
din and several of its fragments. However, we use them here for ease 
of comparison with earlier data. 
potential sites for N-linked glycosylation (Fig. 6).  A com- 
puter search of the National Biomedical Research Founda- 
tion and  Newat  (Doolittle,  1981) data bases  revealed that 
this area (residues 285-354) also shows homology with the 
NH2-terminal prosegment of human (36.6% identity in a 71 
amino acid overlap) and bovine (37.5 % identity in a 72 amino 
acid overlap) type I procollagen, respectively (Horlein et al., 
1979; Chu et al., 1984). Interestingly, short sequences in this 
area also show homology with human fibronectin (50 % iden- 
tity in a  16 amino acid overlap, thrombospondin residues 
298-313) and human von Willebrand factor (53.8 % identity 
in a  13 amino acid overlap, thrombospondin residues 348- 
360)  (Garcia-Pardo et al.,  1983;  Kornblihtt et al.,  1985; 
Ginsburg  et al.,  1985).  It is possible that these short se- 
quences are involved in a common aspect of matrix protein 
function in much the same way the RGD sequence is involved 
in cell adhesion (see below). 
The 85,000-D tryptic fragment, which overlaps the 70,000- 
D chymotryptic fragment (Fig. 6), has been reported to con- 
lain a cross-linking site for factor XIIIa (Bale et al.,  1985). 
The sequence Gly-Gln-Gln (GQQ) has been shown to be the 
transglutaminase reactive site in the "y-chain of fibrinogen 
(Chen and Doolittle,  1971), and Ala-Gln-Gln (AQQ) is the 
major reactive site in fibronectin (McDonough et al.,  1981). 
Thrombospondin contains  the sequence I(381)-Q(382)-Q(383) 
in the region, which should be included in the 85,000-D tryp- 
tic fragment. 
The precise COOH terminal of the 70,000-D chymotryptic 
fragment is not known. The molecular weight would predict 
that all of the type I and all or most of the type 2 repeating 
sequences are located in this fragment (Fig. 6). A computer 
search (Lipman and Pearson,  1985)  of known protein se- 
quences revealed that the type 1 repeating sequences are ho- 
mologous with the COOH terminal of circumsporozoite pro- 
teins from Plasmodium falciparum (38.3 % identify in a 47 
amino acid overlap) and Plasmodium knowlesi (31.4 % iden- 
tify in a 51 amino acid overlap) (Ozaki et al.,  1983; Dame 
et al.,  1984).  The significance of this finding is not clear. 
Thrombospondin has been reported to be involved in the 
adhesion of  Plasmodiumfalciparum-infected red blood cells 
to  endothelial cells  (Roberts et al.,  1985).  However, this 
phenomenon involves the trophozoite or schizont stage of 
the parasite, whereas the sporozoite stage infects hepatocytes. 
The cysteine-rich segment of the circumsporozoite protein is 
conserved between isolates and species of the parasite and 
has been proposed to be involved in interactions with cell 
surfaces (Dame et al., 1984). The region of thrombospondin 
that contains the three type 1 repeats, which are homologous 
with this segment of the circumsporozoite protein, is known 
to bind to several matrix proteins (Fig.  6) (Mumby et al., 
1984;  Lawler et al.,  1986b).  The precise function of this 
motif in  both  Plasmodium  proteins  and  thrombospondin 
clearly deserves further investigation. 
The type 2 repeats are somewhat homologous with mouse 
epidermal growth factor precursor (24 % homology in a 200 
amino acid overlap by the program of Lipman and Pearson, 
1985; see also Gray et al.,  1983; Scott et al.,  1983) (Fig. 4). 
Transforming growth factors, vaccinia virus growth factor, 
coagulation factors IX and X, tissue plasminogen activator, 
urokinase, the low density lipoprotein receptor, and the pro- 
teins encoded by notch and lin-12 genes also have a region 
of  epidermal growth factor (EGF)-like homology, based pri- 
marily on the positions of the six cysteine residues (for a 
review see Bender, 1985). As shown in Fig. 4, the central re- 
gion of thrombospondin, which is homologous with epider- 
mal growth factor precursor, can be arranged as three type 
2  repeats,  which  show  some  homology  with  epidermal 
growth factor-like repeats, especially in the arrangement of 
cysteine residues. The significance of the homologies among 
these diverse proteins is uncertain. One possibility is that the 
epidermal  growth  factor-like module  is  involved in  pro- 
tein-protein interactions in each case. The 70,000-D chymo- 
tryptic fragment of thrombospondin binds to a  variety of 
other proteins (Fig. 6) (Mumby et al.,  1984; Lawler et al., 
1986). Some of these affinities are shared with other proteins 
in the family of proteins which contain some homologies 
with epidermal growth factor. For example, tissue plasmino- 
gen activator and urokinase both interact with plasminogen, 
as does thrombospondin, and tissue plasminogen activator 
and thrombospondin both bind fibronectin and fibrinogen 
(Leung and Nachman,  1982; Lahav et al.,  1984; Silverstein 
et al.,  1984).  Several lines of investigation are suggested by 
these homologies and parallels. 
The type 3 homologies are typified by the consensus se- 
quence shown in Fig. 5. The primary structure of this region 
suggests that it consists of a series of calcium-binding sites 
immediately adjacent  to  each  other.  The amino  acid  se- 
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the calcium-binding sites of calmodulin, parvalbumin, and 
the  fibrinogen 13- and ~/-subunits  (Kretsinger,  1980;  Hen- 
schen et al., 1983; Dang et al., 1985). The aspartic acid res- 
idues at positions 6,  8,  10,  14,  and  17 contribute oxygens 
for calcium binding. In the type 3A repeating sequence a sec- 
ond set of identically spaced aspartic acid residues is present 
at positions 21, 23, 25, 29, and 32. The glycine residues in 
positions 11 and 26 are also homologous with the calcium- 
binding  sites  of calmodulin and parvalbumin  (Kretsinger, 
1980).  The deletion in the type 3B repeats preserves one 
copy of the aspartate motif, with D(32) replacing D(17) (Fig. 
5).  In  contrast  to  calmodulin  and  parvalbumin,  throm- 
bospondin has aspartic acid residues in positions 17 and 32 
instead of glutamic acid.  The calcium-binding  site of the 
13-chain of fibrinogen also has aspartic acid in this position 
(Henschen et al., 1983). While the immediate coordinates of 
the calcium-binding sites are likely to be similar to those in 
calmodulin, the overall molecular architecture would seem 
to be quite different. Since the sites are so close together in 
thrombospondin, the ct-helical segments which form the EF- 
hand motif are not present (Kretsinger, 1980). The presence 
of  the two cysteine residues in each type 3 homology suggests 
that the structure in thrombospondin is stabilized by disulfide 
bonds rather than by secondary structure. These differences 
may account for the fact that, although some high affinity in- 
teractions have been  reported,  for the  most  part,  throm- 
bospondin  binds  to  calcium  with  a  much  lower  affinity 
(~10  -4)  than does calmodulin  (~10  -6)  (Klee et al.,  1980; 
Lawler and Simons,  1983; Dixit et al.,  1986).  Both the di- 
sulfide-bonded structure and lower affinity for calcium are 
concordant with the fact that thrombospondin functions in an 
extracellular  environment.  The  presence  of two  cysteine 
residues in each of the type 3A and 3B repeats is consistent 
with  recent  reports  that  thrombospondin contains  an  in- 
trachain  disulfide  bond  that  is  protected  from  reducing 
agents by calcium (Turk and Detwiler, 1986). These authors 
also describe a reactive thiol group that is protected by cal- 
cium. The hybrid 3/1 repeat contains an uneven number of 
cysteine residues,  one of which  may be the relevant sulf- 
hydryl group. 
The location of the calcium-binding sites, based on the se- 
quence data presented here, is consistent with the biochemi- 
cal  and electron microscopic data (see Fig.  6  and the in- 
troduction).  The production of the 47,000-  and  53,000-D 
fragments by trypsin and chymotrypsin, respectively, is de- 
pendent upon the  removal of calcium from the  molecule 
(Lawler et al., 1985; Lawler et al., 1986 a, b). Dixit and co- 
workers (1986)  have described two monoclonal antibodies 
that have higher affinity for thrombospondin after EDTA 
treatment. The binding of one of these antibodies, designated 
A6.1, to thrombospondin has a calcium ion concentration de- 
pendence similar to the structural parameters (50-120 ~tM). 
The binding of the other antibody, designated D4.6, has a 
sharp transition at a calcium ion concentration of 100 nM. 
Epitope mapping indicates that monoclonal antibodies A6.1 
and D4.6 bind to the region of polypeptide that produces the 
47,000-D tryptic fragment (Dixit et al., 1986). The structure 
of this region is profoundly affected by the removal of cal- 
cium (Lawler et al., 1985; Dixit et al., 1986). In the presence 
of calcium this region is part of globular region C. When cal- 
cium is removed from the molecule this region adopts an ex- 
tended conformation. 
The RGD sequence, which is present in the last type 3 ho- 
mology of thrombospondin, mediates the interaction of sev- 
eral extracellular matrix proteins with cell surfaces (for a 
review see Ruoslahti and Pierschbacher, 1986).  The glyco- 
protein IIb/IIIa complex of platelets has been identified as a 
receptor that recognizes the RGD sequence of fibronectin, 
fibrinogen, von Willebrand factor, and vitronectin (Gardner 
and Hynes, 1985; Pytela et al.,  1986).  Parallel studies with 
thrombospondin indicated that this receptor may also bind 
thrombospondin  weakly  (Pytela et  al.,  1986).  Thrombo- 
spondin has been reported to associate with the surface of 
thrombin-treated normal platelets in the presence of EDTA, 
which inactivates IIb/IIIa, and with the surface of thrombin- 
treated thrombasthenic platelets, which lack IIb/IIIa (Hour- 
dille et al., 1985). By contrast, monoclonal antibodies to the 
glycoprotein IIb/IIIa complex inhibit the binding of throm- 
bospondin to platelets (Plow et al., 1985). Wolff et al. (1986) 
have recently described the results  of studies designed to 
measure the binding of thrombospondin to platelets.  They 
detected two classes of binding sites;  one class on resting 
platelets and another that is expressed on thrombin-treated 
platelets in the presence of calcium. One of these classes may 
represent  a  specific  receptor  for thrombospondin,  which 
recognizes the RGDA sequence. Since this sequence is in a 
calcium-sensitive domain of thrombospondin, it is possible 
that its function could be regulated by divalent cation effects. 
After the last type 3A repeating sequence there is a region 
of 25,000 D  in which a well-conserved repeating sequence 
could not be identified. A region of known amino acid se- 
quence is found in this area (Galvin et al.,  1985).  This se- 
quence is the NH2-terminal sequence of an  18,000-D  chy- 
motryptic fragment. The amino acid sequence indicates that 
the peptide portion of this fragment has a molecular weight 
of 13,978 and that there are two potential sites for N-linked 
glycosylation,  which  probably  accounts  for the  observed 
molecular weight (Fig. 6). The 18,000-D fragment is known 
to be disulfide bonded to the rest of the molecule (Fig. 6) 
(Galvin et al.,  1985),  suggesting that C(1149) is  linked to 
C(974). 
In conclusion, the sequence data presented here provide 
structural information that is consonant with all of the prior 
structural and functional data on thrombospondin and offer 
new insights and lines of experimental investigation into the 
function of the molecule. 
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